Recent Antitrust Verdicts Could Reshape Hospital Budgets

In early February, a California federal jury ordered Medtronic to pay nearly $382 million to its competitor Applied Medical for antitrust violations. The jury found that the medical device giant illegally used its monopoly power to crush competition in the advanced bipolar vessel sealing device market.

Section 4 of the Clayton Act requires judges in these cases to allow the plaintiff to recover three times the actual financial harm sustained from anticompetitive conduct. So ultimately, Applied Medical will be awarded more than $1 billion.

The jury deliberated for less than two hours before finding in favor of Applied Medical: Medtronic used anticompetitive tactics, including bundling products for sale in a way that made it nearly impossible for the much smaller Applied Medical to compete. With Medtronic being the largest medical device supplier in the world, Applied Medical can’t offer the array of bundled devices that Medtronic can. Internal documents and emails showed how Medtronic had deployed a sophisticated strategy to crush Applied Medical.

This seems to be a growing trend. The Medtronic decision is similar to a recent $442 million jury decision against J&J’s Biosense Webster. Both cases hinged on the fact that it is illegal to bundle your products and services with something nobody else can offer. In the Biosense case, it was mapping support. In the Medtronic case, it was access to the largest portfolio of medical devices in the world at a discounted price.

The fact that these two similar decisions come within less than a year of each other is an indication that judges and juries are fed up with monopolistic behavior. For hospitals and the overall state of healthcare in the U.S., this is a big deal.

Hospitals Are Losing While Supplier Profits Soar

Times are tough for U.S. hospitals. Prices keep going up, but reimbursement does not. As a result, insurance companies make more money, healthcare technology companies make more money, and pharmaceutical companies make more money. Only the provider loses: The average hospital in the U.S. in August last year had a 1% operating margin. Hospital closures have reached record levels.

In contrast:

· The top five medical device companies control up to 30% of the global market and have a net income of more than $25 billion. The profit pool grew by 38% over the last 5 years to $72 billion.

· Pharmaceutical companies are winners too: The top five control 25% of the market and have net income of almost $90 billion dollars. The profit pool grew by 25% over the last five years to $170 billion.

· The top five insurance companies control 70-75% of the national commercial market and have net income of $30 billion. The profit pool grew by 36% over the last five years to $117 billion.

With this kind of market concentration, two things happen: Providers (hospitals and doctors) have less and less real choice over what they buy—and prices go up.

So, while pharmaceutical, medical device, and health insurance companies have no problem making money, it is different for hospitals. Decreasing reimbursement, increasing costs, and the shift to outpatient care sites squeeze operating margins and limit profit pool growth.

Over the past 15 years, more hospitals have closed than opened. Last year alone, there were at least 23 reported hospital closures or planned closures in the United States. Hospital layoffs are at record highs.

On top of everything else, insurance premiums have been going up, and medical debt is a real problem. Medical debt is, in fact, the leading cause of personal bankruptcy in the United States. The structural problems in our health system are ultimately paid for by the patient.

The concentration of pharmaceutical and medical technology supplies within relatively few large global corporations is part of the problem. More precisely, the abuse of monopoly positions to drive higher profits is very costly for hospitals that are already operating on thin margins.

That’s why it’s so important that the legal system is finally paying attention.

Let’s Turn the Verdicts Into Hospital Leverage

While bundling arrangements might seem to provide benefits, the practice harms hospitals when they pay higher prices and have less choice. Importantly, bundling is illegal when it’s used to block competitors and claim higher profits.

That’s why recent antitrust verdicts are more than headlines. They are practical signals for hospital leadership and supply chain teams to tighten contracting discipline, especially where discounts, rebates, or “portfolio pricing” are tied to purchasing commitments that limit real choice. Every major supplier agreement should be reviewed with a specific lens: Identify where access to pricing on one product line is conditioned on volume or exclusivity in another, where competitive products are effectively locked out, and where contract language makes switching costs punitive or operationally unrealistic.

Vendor management should also reflect the new reality: Hospitals are not obligated to accept take-it-or-leave-it bundling structures as “standard practice.” Contract negotiations should be approached with a documented record of communications and a clear expectation that commercial terms will not be used to block competition. When warranted, hospitals should escalate concerns. The goal is not confrontation for its own sake, but the restoration of genuine choice, fair pricing, and a supply market that rewards clinical value instead of leverage.

And there is an upside worth naming plainly. Holding global healthcare behemoths accountable is a first step toward rebalancing a system where the financial gravity has drifted away from the bedside. When monopoly tactics lose their “business as usual” cover, competition has room to breathe, prices have a reason to behave, and hospitals regain dollars that can be reinvested in staffing, access, technology, and safer, more consistent care.

A more sustainable hospital margin is not a corporate victory; it is a patient victory. Accountability is how the system starts paying for health again, instead of paying a premium for power.